Navigation Links
Myriad publishes clinical utility study for Prolaris
Date:3/3/2014

SALT LAKE CITY, Utah, March 3, 2014 Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, demonstrating that 65 percent of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test. Prolaris is a 46-gene molecular diagnostic test that has been evaluated in 11 clinical studies with more than 5,000 patients.

"Prolaris is an absolute game changer for urologists because it adds meaningful new prognostic information in terms of risk assessment for prostate cancer patients that will improve their care," said E. David Crawford, M.D., head of the Section of Urologic Oncology at the University of Colorado. "In this study, Prolaris led to major changes in therapies with significant reductions or increases in interventional treatments that were based on patients' unique risk profiles."

PROCEDE 500 is a prospective registry study that was designed to evaluate the impact of the Prolaris test on physician treatment recommendations for patients with prostate cancer. In this study of 305 patients, physicians said they would change their treatment plans in 65 percent of cases after receiving the Prolaris report 40 percent of patients had a reduction in therapeutic burden, while 25 percent had an increase in therapeutic burden independent of treatment strategy (i.e., surgery and/or radiation vs. active surveillance and/or watchful waiting). These results are summarized in Table-1 and Table-2 below:

Table 1: Reduction in Therapeutic Burden Among Trial Participants

Number of Patients in the Study Number of Patients Who Saw a Reduction in Therapeutic Burden Percentage Decrease in Therapeutic Burden
305 122 -40%

Table 2: Increase in Therapeutic Burden Among Trial Participants

Number of Patients in the Study Number of Patients Who Saw an Increase in Therapeutic Burden Percentage Increase in Therapeutic Burden
305 76 +25%

The study also evaluated the shift in treatment paradigms from interventional to non-interventional and non-interventional to interventional. Those data appear in the Table-3 and Table-4 below:

Table 3: Planned Interventional Therapy (e.g., Surgery and/or Radiation)

Number of Patients Planned for Interventional Treatment Before Prolaris Test Score Number of Patients Planned for Interventional Treatment After Prolaris Test Score Percentage Decrease in Interventional Therapy
164 103 -37%

Table 4: Planned Non-Interventional Therapy (e.g., Active Surveillance and/or Watchful Waiting)

Number of Patients Planned for Non-Interventional Treatment Before Prolaris Test Score Number of Patients Planned for Non-Interventional Treatment After Prolaris Test Score1 Percentage Increase in Interventional Therapy
141 108 +23%

Importantly, in this study there was an overall 50 percent reduction in surgical interventions and a 30 percent reduction in radiation treatment. Additionally, 96 percent of the 24 patients with initial "undecided" treatment regimens selected non-interventional options after receiving the Prolaris score. These results demonstrate that the Prolaris test is associated with high clinical utility among urologists.

"In multiple clinical studies, Prolaris was shown to provide personalized risk of cancer-specific death, metastases or biochemical failure beyond what is achievable with the Gleason score, clinical stage and PSA data," said Michael Brawer, M.D. vice president of Medical Affairs at Myriad Genetic Laboratories. "PROCEDE 500 demonstrates that the Prolaris score significantly enhances treatment plans for men with localized prostate cancer."

Myriad Submits Updated Clinical Dossier for Medicare Reimbursement Myriad also announced that it has submitted the PROCEDE 500 data as part of the Prolaris clinical dossier to the Centers for Medicare & Medicaid Services (CMS) for Medicare reimbursement. As previously disclosed based on the robust data set from 11 studies with more than 5,000 patients and six publications in peer-reviewed medical journals the company expects a CMS coverage determination on Prolaris by the end of June 2014.

"More than 30,000 men will die from prostate cancer this year, so there is an urgent need to improve clinical care for patients," said Brawer. "Prolaris adds real value to the healthcare system by reducing unnecessary surgeries or exposure to radiation for men at low risk, while increasing medical interventions for men with aggressive prostate cancer, which we believe will save and improve more lives and potentially save the healthcare system more money."


'/>"/>

Contact: Ronald Rogers
rrogers@myriad.com
801-584-3065
Myriad Genetics, Inc.
Source:Eurekalert

Related medicine news :

1. AMP celebrates SCOTUS decision on AMP v. Myriad Case
2. The Laser Outlet Highlights Encouraging Study, Showing Myriad Uses of Medical Lasers
3. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
4. Moffitt researcher publishes book on nutritional management of cancer treatment effects
5. Ear, Nose & Throat Journal publishes research on breakthrough treatment for tonsil stones
6. Natural Sciences Repository Publishes Chromatography and Acidic Compounds Resources
7. ASTRO publishes Safety is No Accident: A Framework for Quality Radiation Oncology and Care
8. Annals of Internal Medicine publishes new CDC recommendations on hepatitis C screening
9. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
10. Using an HRA to Comply with San Francisco's HCSO Requirements - Zane Benefits Publishes Information
11. Zane Benefits Publishes Information About Over-the-Counter (OTC) Medicines, Drugs and HRAs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... ... A recent survey by the Midwest Business Group on Health (MBGH) ... the free preventive care benefits available to them as part of the Affordable Care ... and private employers, MBGH found that only 10% of large employers are aware of ...
(Date:5/5/2016)... Dubuque, IA (PRWEB) , ... May 05, 2016 ... ... his insurance agency’s ongoing community enrichment program serving families of greater Dubuque, IA. ... area’s active duty, reserve and honorably discharged veterans. Donations to Veteran’s Freedom Center ...
(Date:5/5/2016)... ... May 05, 2016 , ... A ... found that more than 40 percent of participating fifth-grade students already have or ... Allergy and Asthma Clinical Research in the Division of Pulmonary, Allergy and Critical ...
(Date:5/5/2016)... YORK (PRWEB) , ... May 05, 2016 , ... TIME ... swimming safety – today announced a new partnership to reach nearly 1 million children ... happen in an instant and is the leading cause of accidental death in children ...
(Date:5/5/2016)... ARIZ. (PRWEB) , ... May 05, 2016 , ... ... president Jennifer Drago presented a talk highlighting the organization’s successful Care Transitions ... in Chicago. , The talk was titled “Minimizing Costs in the Post-Acute Environment ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
(Date:5/4/2016)... -- According to market research "Global Computed Tomography ... 2022 - Industry Insights by Slice Type (High, Mid and ... P&S Market Research, the global computed tomography market ... expected to grow at a CAGR of 5.0% during 2016-2022. ... expected to witness the faster growth, CAGR of 5.3%, during ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Multiple Myeloma Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Multiple Myeloma market valuations and forecast, ...
Breaking Medicine Technology: